Document Detail


Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2.
MedLine Citation:
PMID:  10569139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tumor necrosis factor-alpha (TNF-alpha), a cytokine provided by both immunomodulating and inflammatory activities, has been described to be abnormally increased in the blood of patients affected by malignant lymphomas, particularly NHL. However, the biological and clinical significance of TNF-alpha secretion in malignant lymphomas is still controversial. The present study was carried out to further define TNF-alpha secretion in untreated malignant lymphomas and during low-dose IL-2 immunotherapy. The study included 80 malignant lymphoma patients, 54 of whom were affected by HD and the other 26 by NHL. The mean TNF-alpha serum concentrations observed in untreated lymphoma patients were significantly higher than those seen in the healthy controls, without significant differences between HD and NHL. Moreover, both HD and NHL lymphoma patients at clinical stage III-IV showed significantly higher mean TNF-alpha levels than those at clinical stage I-II. Finally, patients with systemic symptoms had higher mean TNF-alpha concentrations than those without any systemic symptoms, even though statistical significance was observed only for NHL patients. In a second study we have evaluated changes in TNF-alpha levels in seven evaluable lymphoma patients (NHL: 6; HD: 1)--who did not respond to conventional therapies--during subcutaneous low-dose IL-2 (3 MIU/day, 6 days/week for 4 weeks). Long-term stable disease was achieved in four patients with NHL, whereas the other three progressed. In patients with stable disease the mean TNF-alpha concentrations significantly decreased during treatment, whereas they increased in progressing patients. This study, by showing an abnormally enhanced TNF-alpha secretion in both NHL and HD patients with advanced disease and systemic symptoms and a decrease in its levels in patients who achieved disease control on IL-2 immunotherapy, appears to confirm the unfavorable prognostic significance of enhanced TNF-alpha levels in malignant lymphomas.
Authors:
P Lissoni; S Bolis; M Mandalà; S Viviani; E Pogliani; S Barni
Related Documents :
15627639 - Steep elevation of blood interleukin-6 (il-6) associated only with late stages of cache...
18562979 - Il-6 and il-18 in blood may discriminate cirrhotic patients with and without minimal he...
17478989 - Clinical presentation of cutaneous manifestations in complex regional pain syndrome (ty...
7705119 - Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolatio...
16539279 - Circulating levels of beta2-glycoprotein i in thrombotic disorders and in inflammation.
16356539 - Circulating cd40 ligand is elevated only in patients with more advanced symptomatic per...
3576139 - The effect of water exercise therapy given to patients with rheumatoid arthritis.
2238299 - Management of peyronie disease by implantation of inflatable penile prosthesis.
17723289 - Young patients with focal seizures may have the primary motor area for the hand in the ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The International journal of biological markers     Volume:  14     ISSN:  0393-6155     ISO Abbreviation:  Int. J. Biol. Markers     Publication Date:    1999 Jul-Sep
Date Detail:
Created Date:  1999-12-02     Completed Date:  1999-12-02     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8712411     Medline TA:  Int J Biol Markers     Country:  ITALY    
Other Details:
Languages:  eng     Pagination:  167-71     Citation Subset:  IM    
Affiliation:
Division of Radiation Oncology, San Gerardo Hospital, Monza, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Female
Humans
Interleukin-2 / therapeutic use*
Lymphoma / blood,  pathology,  therapy*
Male
Middle Aged
Neoplasm Staging
Tumor Necrosis Factor-alpha / analysis*
Chemical
Reg. No./Substance:
0/Interleukin-2; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase ...
Next Document:  CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies.